146 related articles for article (PubMed ID: 9720824)
1. The interleukin-5 messenger RNA expression in a patient with idiopathic hypereosinophilic syndrome.
Ho KK; Ho AS; Leung RC; Lai CK; Lai KN
Clin Exp Allergy; 1998 Jul; 28(7):889-92. PubMed ID: 9720824
[TBL] [Abstract][Full Text] [Related]
2. Deposits of eosinophil granule proteins in eosinophilic cholecystitis and eosinophilic colitis associated with hypereosinophilic syndrome.
Tajima K; Katagiri T
Dig Dis Sci; 1996 Feb; 41(2):282-8. PubMed ID: 8601370
[TBL] [Abstract][Full Text] [Related]
3. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
4. New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome (HES) and secondary eosinophilic states.
Berki T; Dávid M; Bóné B; Losonczy H; Vass J; Németh P
Pathol Oncol Res; 2001; 7(4):292-7. PubMed ID: 11882909
[TBL] [Abstract][Full Text] [Related]
5. Eosinophils affect functions of in vitro-activated human CD3-CD4+ T cells.
Harfi I; Schandené L; Dremier S; Roufosse F
J Transl Med; 2013 May; 11():112. PubMed ID: 23642304
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome.
Schrezenmeier H; Thomé SD; Tewald F; Fleischer B; Raghavachar A
Exp Hematol; 1993 Feb; 21(2):358-65. PubMed ID: 8425573
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
8. Eosinophilic myositis with eosinophilic cellulitislike skin lesions. Association with increased serum levels of eosinophil cationic protein and interleukin-5.
Trüeb RM; Lübbe J; Torricelli R; Panizzon RG; Wüthrich B; Burg G
Arch Dermatol; 1997 Feb; 133(2):203-6. PubMed ID: 9041834
[TBL] [Abstract][Full Text] [Related]
9. Hypereosinophilic syndrome associated with HIV infection. Military Medical Consortium for Applied Retroviral Research.
Drabick JJ; Magill AJ; Smith KJ; Nutman TB; Benson PM
South Med J; 1994 Apr; 87(4):525-9. PubMed ID: 8153785
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.
Kay AB; Klion AD
Immunol Allergy Clin North Am; 2004 Nov; 24(4):645-66, vii. PubMed ID: 15474864
[TBL] [Abstract][Full Text] [Related]
11. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
12. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
13. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.
Schmid-Grendelmeier P; Altznauer F; Fischer B; Bizer C; Straumann A; Menz G; Blaser K; Wüthrich B; Simon HU
J Immunol; 2002 Jul; 169(2):1021-7. PubMed ID: 12097410
[TBL] [Abstract][Full Text] [Related]
14. A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5.
Brugnoni D; Airó P; Rossi G; Bettinardi A; Simon HU; Garza L; Tosoni C; Cattaneo R; Blaser K; Tucci A
Blood; 1996 Feb; 87(4):1416-22. PubMed ID: 8608231
[TBL] [Abstract][Full Text] [Related]
15. The idiopathic hypereosinophilic syndrome.
Lin DA; Boyce JA
Allergy Asthma Proc; 2003; 24(6):417-20. PubMed ID: 14763243
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-5 mRNA levels in blood and bone marrow mononuclear cells from patients with the idiopathic hypereosinophilic syndrome.
Satoh T; Sun L; Li MS; Spry CJ
Immunology; 1994 Oct; 83(2):308-12. PubMed ID: 7835952
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood CD4 but not CD8 t-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy.
Corrigan CJ; Hamid Q; North J; Barkans J; Moqbel R; Durham S; Gemou-Engesaeth V; Kay AB
Am J Respir Cell Mol Biol; 1995 May; 12(5):567-78. PubMed ID: 7742019
[TBL] [Abstract][Full Text] [Related]
18. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilic disorders in children.
Wagelie-Steffen A; Aceves SS
Curr Allergy Asthma Rep; 2006 Nov; 6(6):475-82. PubMed ID: 17026874
[TBL] [Abstract][Full Text] [Related]
20. Hypereosinophilic syndrome with isolated Loeffler's endocarditis: complete resolution with corticosteroids.
Sen T; Ponde CK; Udwadia ZF
J Postgrad Med; 2008; 54(2):135-7. PubMed ID: 18480530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
